si-f019
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2021 (NCT04851444)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
inhibitor - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04851444 | Phase 1 | Mar 30, 2021 | Baili Pharmaceutical Group, Government of China, SystImmune Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 1 | 1 | 1 | 2021 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
| SystImmune Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1